Skip to main content

Table 3 Comparison between patients with and without pseudolithiasis

From: Ceftriaxone-associated pseudolithiasis in hemodialysis patients: a case series study

 

Pseudolithiasis (n = 10)

No pseudolithiasis (n = 11)

P value

Age (years)

73.9 ± 16.5

71.1 ± 18.7

0.72

Male sex, n (%)

6 (63.6)

7 (61.9)

0.86

DM, n (%)

5 (50.0)

2 (18.2)

0.12

CVD, n (%)

5 (50.0)

4 (36.4)

0.53

Body mass (kg)

50.1 ± 12.5

52.4 ± 9.0

0.64

Body mass index (kg/m2)

19.9 ± 4.3

20.9 ± 2.8

0.53

Ca-containing drug, n (%)

2 (20.0)

3 (27.3)

0.70

Bed-bound, n (%)

6 (60.0)

4 (36.4)

0.28

Fasting, n (%)

0 (0)

1 (15.4)

0.33

Laboratory

 Albumin (g/dL)

2.8 ± 0.8

3.0 ± 0.6

0.35

 Calcium (mg/dL)

9.5 ± 0.6

9.4 ± 0.6

0.75

 Int-PTH (pg/mL)

113.0 (81.0–163.0)

143.0 (94.0–228.0)

0.61

Dose of CTRX (mg/kg/day)

21.3 (18.1–22.4)

17.2 (16.1–19.8)

0.17

Duration of CTRX infusion (day)

12 (8.3–14)

4 (2–8)

0.00872*

Total dose of CTRX (g)

12.5 (9.3–14)

4 (2–8)

0.00476*

  1. DM Diabetes mellitus, CVD Cerebrovascular disease, Ca Calcium, Int-PTH Intact parathormone, CTRX Ceftriaxone
  2. *Statistically significant (P < 0.05)